Search results
Results from the WOW.Com Content Network
In February 2017, the US Patent Office ruled on a patent interference case brought by University of California with respect to patents issued to the Broad Institute, and found that the Broad patents, with claims covering the application of CRISPR-Cas9 in eukaryotic cells, were distinct from the inventions claimed by University of California.
CRISPR interference (CRISPRi) is a genetic perturbation technique that allows for sequence-specific repression of gene expression in prokaryotic and eukaryotic cells. [1] It was first developed by Stanley Qi and colleagues in the laboratories of Wendell Lim , Adam Arkin, Jonathan Weissman , and Jennifer Doudna . [ 2 ]
A U.S. tribunal overseeing patent disputes ruled on Monday that patents on the breakthrough gene-editing technology known as CRISPR belong to Harvard University and the Massachusetts Institute of ...
CRISPR-Cas9 complex. The CRISPR system created a new straightforward way to edit DNA and there was a rush to patent the technique. [6] Doudna and UC Berkeley collaborators applied for a patent and so did a group at the Broad Institute affiliated with the Massachusetts Institute of Technology and Harvard. [47]
InSite Vision Wins Appeal of Patent Interference Litigation Against the University of California, San Francisco Appeal Court Ruling Was Split Decision - Two Judges For and One Against ALAMEDA ...
This interference mechanism is modulated by a modulatory protein, PtiM, binds to one of the interference-mediating proteins, PtiA, and hence achieves the required level of interference. [ 176 ] One study showed that lytic ICP1 phage, which specifically targets Vibrio cholerae serogroup O1, has acquired a CRISPR-Cas system that targets a V ...
For example, corporations may be able to take unfair advantage of patent law or other ways of restricting access to genome editing and thereby may increase the inequalities. There are already disputes in the courts where CRISPR-Cas9 patents and access issues are being negotiated. [78]
Qi led the development of the first catalytically dead Cas9 lacking endonuclease activity (dCas9), which is the basis for CRISPR interference (CRISPRi). His laboratory subsequently developed CRISPR-Genome Organization (CRISPR-GO). Qi is a co-inventor of the University of California patent on the CRISPR gene-editing technology.